TPO and autoimmune thrombocytopenic purpura: As it stands, a range of TPO-RAs, including romiplostim, eltrombopag, avatrombopag, and hetrombopag, have been introduced into clinical practice, thereby broadening the therapeutic arsenal and offering more well-tolerated and effective treatment options for ITP patients [10].